RecruitingOBSERVATIONAL

Evaluation of the Relevance of Antithrombin Prescriptions at Strasbourg University Hospitals

Doctors in Strasbourg are reviewing how a medicine called antithrombin is used in their hospitals. Antithrombin helps prevent blood clots. It's especially important for patients in intensive care who are on machines like kidney dialysis (renal replacement therapy), heart-lung machines (ECMO), or bypass during surgery. These machines can sometimes reduce a patient's natural antithrombin levels, making their blood clot too easily or making other clot-preventing medicines less effective. This study is looking back at patient records from 2022 and 2023 to understand how and why antithrombin was given. This will help them make sure patients get the right treatment at the right time in the future.

At a glance

Status

Recruiting

Sponsor

University Hospital, Strasbourg, France

Enrolment target

160

Start

18 Dec 2024

Estimated completion

31 Dec 2025

Antithrombinemia

What is this study about?

Imagine your blood has a natural bodyguard called antithrombin. Its job is to help stop your blood from clotting too much. If you have too little of this bodyguard (a condition called antithrombinemia), your blood might be more likely to form harmful clots.

This study at Strasbourg University Hospitals is looking into how they use a medicine called antithrombin. This medicine boosts your body's natural clot-stopping ability. It's particularly important for patients in intensive care, especially those who need special machines for severe illnesses, like kidney dialysis or heart-lung support during operations. These machines can accidentally reduce your natural antithrombin, making it harder to control blood clotting.

The hospital wants to check if they are using antithrombin medicine in the best way for these very sick patients. Because these situations are often emergencies, the medicine is kept in the intensive care units ready for immediate use. This study will review past patient records to see how and when the medicine was given between January 2022 and December 2023. By doing this, they hope to improve how they care for patients in the future, making sure everyone gets the most effective and safe treatment.

Key takeaways

This study reviews how antithrombin medicine is used in Strasbourg hospitals.
Antithrombin helps stop blood from clotting too much.
It focuses on patients in intensive care or having surgery who needed this medicine.
The study looks at past patient records from 2022 and 2023.
The goal is to improve future patient care and treatment.
No active patient participation is needed for this study.

Who may be eligible?

This study is looking back at information from patients who have already been treated. You or your loved one would be included if you were an adult (18 years or older) and received antithrombin medicine while in intensive care or during an operation at Strasbourg University Hospitals between January 1, 2022, and December 31, 2023.

This study will not include anyone under 18 years old. Also, if you or your legal representative have previously said you don't want your health information used for research, then your records would not be included in this review.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Were you 18 years old or older when you were treated?
Did you receive antithrombin medicine during your hospital stay?
Was your treatment in an intensive care unit or during an operation?
Did this happen at Strasbourg University Hospitals between January 1, 2022, and December 31, 2023?
Have you *not* previously told the hospital that you don't want your data used for research?

Answer every question to see your result.

What does participation involve?

This study is a review of existing medical records. This means you won't need to do anything extra, attend any appointments, take new medication, or have any follow-up visits specifically for this study. Researchers will simply look at information already collected from your hospital stay if you meet the criteria for inclusion. There is no direct participation required from patients.

Potential risks and benefits

Since this study only involves reviewing existing medical records and no new treatments or procedures, there are no direct risks to patients. There are also no direct benefits to individuals participating, as the study is looking back at past care. However, the information gathered could help doctors improve how they treat patients with low antithrombin levels in the future, potentially benefiting many others.

Locations (1)

Service d'Anesthésie et Réanimation chirurgicale - CHU de Strasbourg - France
Verified postcode
Strasbourg, France· Recruiting

Common questions

What is antithrombin?

Antithrombin is a natural substance in your blood that helps prevent harmful blood clots.

Why is this study being done?

Doctors want to understand how antithrombin medicine is currently used in hospitals to make sure patients get the best care, especially those on life support machines.

Will I need to do anything if my records are included?

No, this study just looks at existing medical records, so you won't need to do anything or attend extra appointments.

Will my personal information be shared?

Researchers will protect your privacy by only using anonymised or de-identified data once it has been processed to improve patient care.

Who is eligible for this study?

Adults (18+) who received antithrombin in intensive care or during surgery at Strasbourg University Hospitals between January 2022 and December 2023.

How to find out more

Xavier DELABRANCHE, MD

xavier.delabranche@chru-strasbourg.fr 33 3 69 55 09 36 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.